AIM Vaccine (HKG:6660) recently submitted a clinical trial application to the US Food and Drug Administration for its mRNA RSV (respiratory syncytial virus) vaccine.
The drugmaker said results from third-party preclinical tests showed that the group's mRNA RSV vaccine had significantly higher humoral and cellular immunity than those of the internationally
marketed mRNA RSV control vaccines, according to a Wednesday bourse filing.